What it is
Tirzepatide is a synthetic peptide. A peptide is a short chain of amino acids, the building blocks of proteins. It switches on two receptors (docking sites on cells) that normally respond to the gut hormones GIP and GLP-1. The FDA label describes it as a GIP receptor and GLP-1 receptor agonist. An agonist is a substance that activates a receptor.
More on what it is and where it came from
In the United States it is a prescription medicine made by Eli Lilly and sold under two brand names. Mounjaro was approved on May 13, 2022 to improve blood sugar control in adults with type 2 diabetes. Its label was later widened to include children aged 10 and older with type 2 diabetes (label change dated December 2025) and, on August 27, 2026, to lower the risk of major heart and blood vessel events in adults with type 2 diabetes who are at high risk. Zepbound was approved on November 8, 2023 for long-term weight management in adults with obesity, or with overweight plus at least one weight-related condition, and on December 20, 2024 for moderate to severe obstructive sleep apnea in adults with obesity.
Both labels carry a boxed warning, the FDA's strongest type, about thyroid C-cell tumors seen in rats. Tirzepatide is also sold online as an unapproved powder labeled "for research use only". The FDA has said these products are of unknown quality and has sent warning letters to sellers. Nothing on this page is advice about using any form of tirzepatide.
Tirzepatide was designed by scientists at Eli Lilly and Company under the code name LY3298176. A 2018 paper in Molecular Metabolism described its discovery, its testing in cells and mice, and the first study in people. Large phase 3 trial programs followed, named SURPASS (type 2 diabetes) and SURMOUNT (obesity). The FDA first approved it in May 2022.
How it is thought to work
According to the FDA label, tirzepatide binds to and activates both the GIP receptor and the GLP-1 receptor. In people with type 2 diabetes it increased the release of insulin and lowered the hormone glucagon, in both cases only when blood sugar was raised. It also slowed the emptying of the stomach, an effect that was largest after the first dose and faded over time. The label states that it decreases food intake and reduces body weight in patients with type 2 diabetes.
More on how it works
A fatty acid chain (a C20 fatty diacid) is attached to the peptide. The label says this lets it bind to albumin, a common blood protein, which keeps it in the body longer. Its half-life (the time for the blood level to fall by half) is about 5 days.
In a 2020 cell study, Eli Lilly scientists reported that tirzepatide activated the GIP receptor more strongly than the GLP-1 receptor, and that its signal at the GLP-1 receptor was 'biased' toward one pathway inside the cell. The authors suggested this might help explain its effects, but this was a laboratory finding and a suggestion, not proof of why it works in people. For sleep apnea, the FDA said the improvement seen in trials was likely related to weight loss.
What is established in people
In people with type 2 diabetes, large randomized trials showed tirzepatide lowered blood sugar and body weight, and in one trial of 1,879 patients it lowered both more than semaglutide over 40 weeks. In people with obesity, a 72-week placebo-controlled trial of 2,539 adults found average weight loss of 15% to 21%, and two one-year trials found fewer breathing pauses in sleep apnea. What is less settled: weight returned in most people who stopped (SURMOUNT-4), about a quarter of the weight lost was lean mass in a small scan substudy, and the largest heart-outcomes trial showed tirzepatide was not worse than dulaglutide but did not prove it was better. Almost all of these trials were paid for by the maker, and none tested the unapproved products sold online.
What the studies found
11 studies, human trials first. Each links to the paper or registry record.
- Human trial2025
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight
On tirzepatide, body weight fell 21.3%, fat mass fell 33.9% and lean mass (which includes muscle) fell 10.9%.
Full finding, who was studied, and limits
Who: 160 of the 2,539 SURMOUNT-1 participants who had body scans (DXA) at the start and at week 72: 124 on tirzepatide and 36 on placebo.
On tirzepatide, body weight fell 21.3%, fat mass fell 33.9% and lean mass (which includes muscle) fell 10.9%. On placebo the figures were 5.3%, 8.2% and 2.6%. In both groups about 75% of the weight lost was fat and about 25% was lean mass.
Read with care: A small substudy, with some analyses done after the fact (post hoc). DXA measures lean mass, not muscle strength or function. An erratum to this paper was published in November 2025; the erratum itself was not opened.
- Human trial2025
Tirzepatide for Obesity Treatment and Diabetes Prevention
At 176 weeks, average weight change was -12.3%, -18.7% and -19.7% in the three tirzepatide groups, against -1.3% with placebo.
Full finding, who was studied, and limits
Who: The 1,032 SURMOUNT-1 participants who had both obesity and prediabetes at the start. They stayed on their assigned tirzepatide dose or placebo for 176 weeks, followed by 17 weeks off treatment.
At 176 weeks, average weight change was -12.3%, -18.7% and -19.7% in the three tirzepatide groups, against -1.3% with placebo. Type 2 diabetes was diagnosed in 1.3% of those on tirzepatide and 13.3% of those on placebo. After 17 weeks off treatment the figures were 2.4% and 13.7%.
Read with care: Covers only the subgroup with prediabetes. Funded by Eli Lilly. The off-treatment period was short, so it does not show whether the lower rate of diabetes lasts.
- Human trial2025
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Death from cardiovascular causes or a worsening heart failure event occurred in 9.9% of the tirzepatide group and 15.3% of the placebo group (hazard ratio 0.62, 95% confidence interval 0.41 to 0.95).
Full finding, who was studied, and limits
Who: 731 patients with obesity and a type of heart failure in which the heart still pumps out a normal share of its blood (ejection fraction of 50% or more). 364 received tirzepatide and 367 placebo. Median follow-up was 104 weeks.
Death from cardiovascular causes or a worsening heart failure event occurred in 9.9% of the tirzepatide group and 15.3% of the placebo group (hazard ratio 0.62, 95% confidence interval 0.41 to 0.95). The difference came from fewer worsening heart failure events (8.0% against 14.2%). Cardiovascular deaths were 8 with tirzepatide and 5 with placebo, a difference too small to interpret. Symptom scores improved more with tirzepatide. Side effects led 6.3% on tirzepatide and 1.4% on placebo to stop treatment.
Read with care: A mid-sized trial with few events, so the result is less certain than the headline suggests. It did not show fewer deaths. As of the labels read for this page (August 2026 versions), heart failure is not an FDA-approved use. Funded by Eli Lilly.
New England Journal of Medicine (SUMMIT, NCT04847557) · pubmed.ncbi.nlm.nih.gov
- Human trial2025
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Average weight change at 72 weeks was -20.2% with tirzepatide and -13.7% with semaglutide.
Full finding, who was studied, and limits
Who: 751 adults with obesity and without type 2 diabetes, randomly assigned to tirzepatide or semaglutide, each at the highest dose they could tolerate, for 72 weeks. Open-label phase 3b trial.
Average weight change at 72 weeks was -20.2% with tirzepatide and -13.7% with semaglutide. Waist size fell by 18.4 cm with tirzepatide and 13.0 cm with semaglutide. More people on tirzepatide reached weight losses of at least 10%, 15%, 20% and 25%. Stomach and gut side effects were the most common in both groups, mostly mild to moderate.
Read with care: Open-label: participants and doctors knew which drug was given, which can influence behavior and reporting. Funded by Eli Lilly, the maker of tirzepatide. It measured weight and waist size, not health outcomes such as heart attacks.
New England Journal of Medicine (SURMOUNT-5, NCT05822830) · pubmed.ncbi.nlm.nih.gov
- Human trial2025
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
Cardiovascular death, heart attack or stroke occurred in 12.2% of the tirzepatide group and 13.1% of the dulaglutide group (hazard ratio 0.92, 95.3% confidence interval 0.83 to 1.01).
Full finding, who was studied, and limits
Who: 13,299 adults with type 2 diabetes and established cardiovascular disease were randomized to tirzepatide or dulaglutide (an older GLP-1 medicine). Double-blind. The FDA label gives a median follow-up of 210.1 weeks (about four years).
Cardiovascular death, heart attack or stroke occurred in 12.2% of the tirzepatide group and 13.1% of the dulaglutide group (hazard ratio 0.92, 95.3% confidence interval 0.83 to 1.01). This met the test for 'non-inferiority' (not worse than dulaglutide) but did not meet the test for superiority (P = 0.09). The FDA label states that superiority to dulaglutide was not established. The label also reports deaths from any cause in 8.5% against 10.1%, but notes this comparison was not statistically controlled.
Read with care: This is the largest tirzepatide trial found, and it tempers the hype: tirzepatide was not shown to be better for the heart than an existing medicine. The comparison was against another active drug, not placebo. The published paper and the FDA label give slightly different counts (801 of 6,586 against 803 of 6,647 for tirzepatide) because they use different analysis groups. Funded by Eli Lilly.
New England Journal of Medicine (SURPASS-CVOT, NCT04255433) · pubmed.ncbi.nlm.nih.gov
- Human trial2024
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
During the first 36 weeks, average weight fell by 20.9%.
Full finding, who was studied, and limits
Who: 783 adults with obesity or overweight (no diabetes) took tirzepatide for 36 weeks. The 670 who completed that phase were then randomly assigned to keep taking tirzepatide (335) or switch to placebo (335) for another 52 weeks, without knowing which.
During the first 36 weeks, average weight fell by 20.9%. Over the next 52 weeks, those switched to placebo regained an average of 14.0% of their weight, while those who continued lost a further 5.5%. At the end, 89.5% of those who continued had kept at least 80% of their earlier weight loss, against 16.6% of those switched to placebo.
Read with care: This trial tempers the headline weight-loss numbers: much of the lost weight returned within a year of stopping. Only people who tolerated the drug through the first 36 weeks were randomized, so results apply to that group. Several authors were Eli Lilly employees.
- Human trial2024
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
The main measure was the apnea-hypopnea index (AHI), the number of breathing pauses or shallow-breathing events per hour of sleep.
Full finding, who was studied, and limits
Who: Two double-blind phase 3 trials lasting 52 weeks in adults with moderate to severe obstructive sleep apnea and obesity, without type 2 diabetes. One trial enrolled people not using a breathing machine (PAP) and the other enrolled people using one. The FDA reports 469 participants in total.
The main measure was the apnea-hypopnea index (AHI), the number of breathing pauses or shallow-breathing events per hour of sleep. Starting from about 50 events per hour, AHI fell by 25.3 events per hour with tirzepatide against 5.3 with placebo in the first trial, and by 29.3 against 5.5 in the second. Weight and several other secondary measures also improved more with tirzepatide.
Read with care: Participants all had obesity, so the results do not apply to sleep apnea in people without obesity. The FDA said the improvement was likely related to weight loss. One year long. Funded by Eli Lilly.
New England Journal of Medicine (SURMOUNT-OSA, NCT05412004) · pubmed.ncbi.nlm.nih.gov
- Human trial2022
Tirzepatide Once Weekly for the Treatment of Obesity
Average weight change at 72 weeks was -15.0%, -19.5% and -20.9% in the three tirzepatide groups, against -3.1% with placebo.
Full finding, who was studied, and limits
Who: 2,539 adults with obesity, or with overweight plus at least one weight-related complication, and without diabetes. Randomly assigned to one of three tirzepatide dose groups or placebo for 72 weeks. Double-blind phase 3 trial.
Average weight change at 72 weeks was -15.0%, -19.5% and -20.9% in the three tirzepatide groups, against -3.1% with placebo. Between 85% and 91% of people on tirzepatide lost at least 5% of their body weight, against 35% on placebo. In the two higher dose groups, 50% and 57% lost at least 20%, against 3% on placebo. Between 4.3% and 7.1% of people on tirzepatide stopped treatment because of side effects, against 2.6% on placebo.
Read with care: Funded by Eli Lilly. All participants also received lifestyle support. People with diabetes were excluded. The 72-week result says nothing about what happens after stopping (see SURMOUNT-4 below).
New England Journal of Medicine (SURMOUNT-1, NCT04184622) · pubmed.ncbi.nlm.nih.gov
- Human trial2021
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
HbA1c (a measure of average blood sugar over about three months) fell by 2.01, 2.24 and 2.30 percentage points in the three tirzepatide groups, against 1.86 points with semaglutide.
Full finding, who was studied, and limits
Who: 1,879 adults with type 2 diabetes already taking metformin, randomly assigned to one of three tirzepatide dose groups or to semaglutide, for 40 weeks. Open-label phase 3 trial.
HbA1c (a measure of average blood sugar over about three months) fell by 2.01, 2.24 and 2.30 percentage points in the three tirzepatide groups, against 1.86 points with semaglutide. All three tirzepatide groups were statistically better than semaglutide. Tirzepatide groups also lost 1.9 to 5.5 kg more weight than the semaglutide group. Nausea affected 17% to 22% on tirzepatide and 18% on semaglutide. Serious adverse events were reported in 5% to 7% on tirzepatide and 3% on semaglutide.
Read with care: Open-label, meaning patients and doctors knew which drug was being given. It lasted 40 weeks and compared against a single semaglutide dose. Funded by Eli Lilly. It measured blood sugar and weight, not heart attacks, strokes or deaths.
New England Journal of Medicine (SURPASS-2, NCT03987919) · pubmed.ncbi.nlm.nih.gov
- Human trial2018
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
This was the first report of tirzepatide in people.
Full finding, who was studied, and limits
Who: Cells, mice, and a phase 1 study in which 142 people (healthy volunteers and patients with type 2 diabetes) received at least one dose of LY3298176, the comparison drug dulaglutide, or placebo. Treatment lasted up to 4 weeks.
This was the first report of tirzepatide in people. Over 4 weeks, patients with type 2 diabetes on the higher dose levels had larger falls in fasting blood sugar than those on placebo, and both healthy volunteers and patients lost more weight than those on placebo (roughly 2 to 5 kg more, depending on the group).
Read with care: Small, short, early-stage study run and written by the maker's own scientists. It was designed to test safety and whether the idea worked at all, not long-term benefit or harm.
- Cell study2020
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Tirzepatide acted more strongly at the GIP receptor than at the GLP-1 receptor.
Full finding, who was studied, and limits
Who: Laboratory cell systems carrying human GIP and GLP-1 receptors.
Tirzepatide acted more strongly at the GIP receptor than at the GLP-1 receptor. At the GLP-1 receptor its signaling favored one pathway inside the cell (cAMP) over another (beta-arrestin recruitment). The authors suggested these features may help explain its effects.
Read with care: Cell experiments only. They show how the molecule behaves at receptors in a dish, not why patients in trials lost weight or had lower blood sugar. Authors were employed by the maker.
Safety findings
- Boxed warning on both labels: in rats, tirzepatide caused thyroid C-cell tumors that increased with dose and length of treatment, at exposures relevant to people. The label says it is unknown whether it causes such tumors, including medullary thyroid carcinoma (a type of thyroid cancer), in humans. It is contraindicated (must not be used) in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. Source: dailymed.nlm.nih.gov
- Most common side effects in the Zepbound weight-management trials (label table, tirzepatide dose groups against placebo): nausea 25% to 29% against 8%; diarrhea 19% to 23% against 8%; vomiting 8% to 13% against 2%; constipation 11% to 17% against 5%; abdominal pain 9% to 10% against 5%; hair loss 4% to 5% against 1%. Between 4.8% and 6.7% stopped treatment because of side effects, against 3.4% on placebo. Source: dailymed.nlm.nih.gov
- Most common side effects in the Mounjaro diabetes trials (placebo-controlled pool): nausea 12% to 18% against 4% on placebo; diarrhea 12% to 17% against 9%; decreased appetite 5% to 11% against 1%; vomiting 5% to 9% against 2%. Stomach and gut side effects led 3.0% to 6.6% to stop treatment, against 0.4% on placebo. Most nausea, vomiting and diarrhea occurred while the dose was being raised and lessened over time. Source: accessdata.fda.gov
- Other warnings on the current labels: severe stomach and gut reactions (not recommended in severe gastroparesis, a condition of slow stomach emptying); acute pancreatitis (inflammation of the pancreas); acute gallbladder disease; low blood sugar, mainly when combined with insulin or sulfonylurea medicines; acute kidney injury linked to fluid loss; serious allergic reactions; worsening of diabetic eye disease in people who already have it; and food or liquid entering the lungs during general anesthesia or deep sedation. Source: dailymed.nlm.nih.gov
4 more safety findings
- In Mounjaro clinical studies, 14 events of acute pancreatitis were confirmed in 13 tirzepatide-treated adults (0.23 patients per 100 years of exposure) against 3 events in 3 comparator-treated patients (0.11 per 100 years). Acute gallbladder disease was reported in 0.6% on tirzepatide and 0% on placebo. Average heart rate rose by 2 to 4 beats per minute, against 1 with placebo; the label says the clinical relevance is uncertain. Source: accessdata.fda.gov
- Pregnancy and contraception: the Mounjaro label says human data in pregnancy are insufficient and that animal studies suggest possible risk to the fetus. Because tirzepatide slows stomach emptying, it lowered blood levels of an oral contraceptive in a drug-interaction study, and the label carries advice for prescribers about this. Source: accessdata.fda.gov
- Suicidal thoughts: on January 13, 2026 the FDA said its review found no increased risk of suicidal thoughts or behavior with GLP-1 medicines and asked for that warning to be removed from the Saxenda, Wegovy and Zepbound labels. The review included an analysis of 91 placebo-controlled trials with 107,910 patients. The Zepbound label read for this page lists that warning as removed (February 2026). Source: fda.gov
- Unapproved and compounded products: as of May 31, 2026 the FDA had received more than 730 adverse event reports for compounded tirzepatide, and said such reports are likely undercounted and cannot always be tied to the drug. The FDA also reported fraudulent products with false labels, and warned that tirzepatide sold online may be counterfeit or contain the wrong amount of ingredient, a wrong ingredient, or none. There are no human safety studies of 'research use' tirzepatide products. Source: fda.gov
Rules and status
FDA-approved prescription medicine as Mounjaro and Zepbound (Eli Lilly). Compounded tirzepatide is not FDA-approved. Tirzepatide sold online as 'for research use' is an unapproved drug in the FDA's view.
The full history, with dates
Approvals: Mounjaro, May 13, 2022 (blood sugar control in adults with type 2 diabetes); label extended to children aged 10 and older (label change dated 12/2025; exact approval day not confirmed); cardiovascular risk reduction in adults with type 2 diabetes at high risk, added to the label dated August 27, 2026. Zepbound, November 8, 2023 (chronic weight management); December 20, 2024 (moderate to severe obstructive sleep apnea in adults with obesity). Both labels carry a boxed warning on thyroid C-cell tumors. Shortage and compounding: tirzepatide injection was added to the FDA drug shortage list on December 15, 2022, which allowed wider compounding. The FDA removed it on October 2, 2024. Compounders sued on October 7, 2024 and a court sent the decision back to the FDA on October 11, 2024. On December 19, 2024 the FDA issued a declaratory order confirming the shortage was resolved. It gave state-licensed pharmacies (503A) until February 18, 2025 and outsourcing facilities (503B) until March 19, 2025, later tied to a court ruling; the court denied the compounders' request for an injunction on March 5, 2025, and the FDA states these grace periods have ended. FDA's page (current as of April 1, 2026) says tirzepatide is on neither the drug shortage list nor the 503B bulks list, so outsourcing facilities may not compound from bulk tirzepatide, and 503A pharmacies fall under the rule against making what are essentially copies of an approved drug. 2026 actions: February 6, 2026, the FDA announced it intends to restrict GLP-1 ingredients used in non-approved compounded drugs that are mass-marketed, and said such products cannot be described as generic or the same as approved drugs. March 3, 2026, it announced 30 warning letters to telehealth companies. April 30, 2026, it proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need; this was formally published in the Federal Register on May 1, 2026 (91 FR 23431) and the comment period was extended to July 30, 2026. No final decision was found as of November 18, 2026 (FDA's compounding policies page, current as of September 9, 2026, lists only the proposal). 'Research use' products: FDA's page (current as of October 1, 2026) says it has warned companies selling unapproved tirzepatide falsely labeled 'for research purposes' or 'not for human consumption', and urges consumers not to buy them. For example, a warning letter dated August 24, 2026 to Peptide Partners LLC named a tirzepatide product and stated that the 'research use only' label did not change that it was an unapproved new drug intended for human use. HHS peptide policy: tirzepatide is not among the six peptides named in the HHS draft enforcement-discretion policy announced on October 30, 2026 (91 FR 68526); Appendix A of the policy (on hhs.gov, read from an Internet Archive capture of November 15, 2026) names exactly BPC-157, epitalon, KPV, MOTS-c, semax and TB-500.
Source: fda.gov (source dated 2026-10-01)
In sport: Not on the WADA Prohibited List: tirzepatide is not named in the 2026 List (in force from January 1, 2026) or the 2027 List (in force from January 1, 2027). Class S0 (Non-approved substances) does not catch it, because S0 covers only substances 'with no current approval by any governmental regulatory health authority for human therapeutic use', and tirzepatide is FDA-approved. It is on the WADA Monitoring Program, which tracks substances that are not banned: listed for 2026 ('Markers of semaglutide and tirzepatide', in and out of competition) and for 2027 ('GLP-1 agonists: semaglutide and tirzepatide'). When WADA published the 2027 List on September 21, 2026, it said the status of GLP-1 receptor agonists, including tirzepatide, remains unchanged for 2027 pending more data, and that it is running studies in athletes. WADA
Claims and what the evidence supports
| What people say | What the evidence supports |
|---|---|
| Research-grade tirzepatide sold online is the same thing as Mounjaro or Zepbound. | The FDA says these are unapproved drugs of unknown quality that may be counterfeit or contain the wrong amount of ingredient, a wrong ingredient, or none. It has sent warning letters to sellers. None of the trials on this page tested these products. Source: fda.gov |
| Compounded tirzepatide is a generic or FDA-approved version. | Compounded drugs are not FDA-approved. In February 2026 the FDA said companies cannot claim compounded products are generic versions of, or the same as, approved drugs. The shortage that had allowed wider compounding was declared resolved in a December 19, 2024 order. Source: fda.gov |
| The weight stays off once you stop. | In SURMOUNT-4, people switched to placebo after 36 weeks regained an average of 14.0% of their body weight over the next year. Only 16.6% kept at least 80% of their earlier loss, against 89.5% of those who continued. Source: pubmed.ncbi.nlm.nih.gov |
| The weight lost is all fat. | In a scan substudy of 160 SURMOUNT-1 participants, about 75% of the weight lost was fat and about 25% was lean mass. Lean mass fell 10.9% on tirzepatide against 2.6% on placebo. Source: pubmed.ncbi.nlm.nih.gov |
| It leads to more weight loss than semaglutide. | Supported by one head-to-head trial: in SURMOUNT-5 (751 adults, 72 weeks) average weight change was -20.2% with tirzepatide against -13.7% with semaglutide. The trial was open-label and paid for by tirzepatide's maker, and it did not measure long-term health outcomes. Source: pubmed.ncbi.nlm.nih.gov |
| It is proven to protect the heart better than older drugs of its kind. | Not shown. In SURPASS-CVOT (13,299 patients with type 2 diabetes and cardiovascular disease), tirzepatide was not worse than dulaglutide for cardiovascular death, heart attack or stroke, but the test for being better was not met (P = 0.09). The FDA label says superiority was not established. Source: pubmed.ncbi.nlm.nih.gov |
| It is banned in sport. | It is not on the WADA Prohibited List for 2026 or 2027. WADA monitors its use and said in September 2026 that there was not yet enough evidence to decide whether it meets the criteria for a ban. Source: wada-ama.org |
What a genuine lab report should show
- Identity by mass spectrometry: the measured mass should match tirzepatide's expected molecular weight of about 4813.5 Da (FDA label: 4813.53 Da; PubChem monoisotopic mass: 4810.52 Da). A report that shows a different mass, or no mass data, does not confirm identity.
- Purity by HPLC (a method that separates a sample into its components), with the actual chromatogram shown, the purity percentage, and any impurity peaks listed. Tirzepatide is a long, modified peptide (39 amino acids, two non-standard residues and a fatty acid side chain), so incomplete or mis-built chains are a realistic impurity.
- Content: the measured amount of peptide in the vial compared with the amount on the label. The FDA has warned that tirzepatide sold online may contain too little, too much, or no active ingredient.
- Traceability: the report should name the testing laboratory, the lot or batch number, and the test date, and the lot number should match the product. The FDA has documented tirzepatide products carrying false label information, including pharmacy names that did not exist.
- What a lab report cannot do: a certificate of analysis does not make a product FDA-approved, and it does not show the product is sterile or safe unless those tests were actually run and reported. The approved medicines are made under FDA oversight; 'research use' products are not.
What is not known
- Whether the thyroid C-cell tumors seen in rats are relevant to humans. The label says this has not been determined.
- Whether tirzepatide lowers heart attacks, strokes or deaths compared with no treatment. The one large outcomes trial compared it with another active drug and did not show superiority. Outcome trials in people with obesity but without diabetes were not looked up for this page.
- Long-term effects beyond about four years of treatment, and the practical meaning of the lean mass loss seen on scans (strength and function were not measured in the substudy read).
- The FDA's April 30, 2026 proposal to exclude tirzepatide from the 503B bulks list: no final decision was found as of November 18, 2026. The compounders' lawsuit over the shortage decision was reported as on appeal, but this was not confirmed from a primary source.
- WADA has said a decision on GLP-1 medicines depends on studies in athletes that are still running. The status could change in a future list.
- SURPASS-CVOT numbers differ slightly between the published paper and the FDA label (different analysis groups). The hazard ratio is the same in both.
- The exact approval date for the pediatric type 2 diabetes use was not confirmed; the label shows the change as 12/2025.
- FDA's count of adverse event reports for compounded tirzepatide (more than 730 as of May 31, 2026) is not a rate and cannot show cause; the true number of harms is unknown.
Sources
All 35 sources
- PubChem: Tirzepatide (CID 156588324). pubchem.ncbi.nlm.nih.gov
- DailyMed: Mounjaro prescribing information (revised 8/2026). dailymed.nlm.nih.gov
- DailyMed: Zepbound prescribing information (revised 8/2026). dailymed.nlm.nih.gov
- FDA: Mounjaro prescribing information PDF (revised 01/2026). accessdata.fda.gov
- FDA: Mounjaro supplement approval letter, cardiovascular indication (signed August 27, 2026). accessdata.fda.gov
- FDA Drug Trials Snapshot: Mounjaro (approval May 13, 2022). fda.gov
- FDA press announcement: Zepbound approved for chronic weight management (November 8, 2023). fda.gov
- FDA press announcement: Zepbound approved for obstructive sleep apnea (December 20, 2024). fda.gov
- FDA declaratory order: resolution of tirzepatide shortage (December 19, 2024). fda.gov
- FDA: policies for compounders as GLP-1 supply stabilizes (current as of April 1, 2026). fda.gov
- FDA: concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026). fda.gov
- FDA press statement: intent to act against non-FDA-approved GLP-1 drugs (February 6, 2026). fda.gov
- FDA press announcement: 30 telehealth companies warned over compounded GLP-1 marketing (March 3, 2026). fda.gov
- FDA press announcement: proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026). fda.gov
- Federal Register (FDA notice): extension of comment period to July 30, 2026. public-inspection.federalregister.gov
- FDA: Human Drug Compounding Policies and Rules (current as of September 9, 2026). fda.gov
- FDA warning letter: Peptide Partners LLC (August 24, 2026). fda.gov
- FDA Drug Safety Communication: removal of suicidal behavior and ideation warning (January 13, 2026). fda.gov
- WADA 2027 Prohibited List, published 21 September 2026, in force 1 January 2027. wada-ama.org
- WADA: 2027 Monitoring Program. wada-ama.org
- WADA: 2026 Monitoring Program. wada-ama.org
- WADA: 2026 Prohibited List. wada-ama.org
- Coskun et al. 2018, Molecular Metabolism (discovery and phase 1). pubmed.ncbi.nlm.nih.gov
- Willard et al. 2020, JCI Insight (receptor pharmacology). pubmed.ncbi.nlm.nih.gov
- Frias et al. 2021, NEJM (SURPASS-2). pubmed.ncbi.nlm.nih.gov
- Jastreboff et al. 2022, NEJM (SURMOUNT-1). pubmed.ncbi.nlm.nih.gov
- Aronne et al. 2024, JAMA (SURMOUNT-4). pubmed.ncbi.nlm.nih.gov
- Malhotra et al. 2024, NEJM (SURMOUNT-OSA). pubmed.ncbi.nlm.nih.gov
- Jastreboff et al. 2025, NEJM (SURMOUNT-1 three-year analysis). pubmed.ncbi.nlm.nih.gov
- Packer et al. 2025, NEJM (SUMMIT). pubmed.ncbi.nlm.nih.gov
- Look et al. 2025, Diabetes Obes Metab (body composition substudy). pubmed.ncbi.nlm.nih.gov
- Aronne et al. 2025, NEJM (SURMOUNT-5). pubmed.ncbi.nlm.nih.gov
- Nicholls et al. 2025, NEJM (SURPASS-CVOT). pubmed.ncbi.nlm.nih.gov
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (the six peptides) and Appendix B (HHS reasoning); read from an Internet Archive capture of 15 November 2026. hhs.gov
- Federal Register, 30 October 2026, 91 FR 68526: HHS notice of the draft enforcement discretion policy. govinfo.gov
Sources last checked 2026-11-18.
This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.